ClinicalTrials.gg
CompletedNCT00811616MaximusUpdated May 16, 2025

A Safety and Efficacy of Supralimus™ Core™ Sirolimus Eluting Stent at MAX DDHV Institute

An interventional study of Supralimus-Core™ and Supralimus™ Core™ Sirolimus eluting stent in Coronary Artery Disease, sponsored by Sahajanand Medical Technologies Limited. Completed at 1 site in India. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-16.

Sponsored by Sahajanand Medical Technologies Limited · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
105
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 62 studies in Coronary Artery Disease with a site in India — 6 open to participants now, 13 under way, 3 of them phase 3. Coronary Artery Disease · India.

Enrollment
33rd of 43
105 · median 754
Started
2006
with 2 others
No phase
24 of 62
3 open now
Registered
7th of 62
by date
Lead sponsor
4 of 62
Sahajanand Medical Technologies Limited

Among the 62 studies in Coronary Artery Disease with a site in India, this one is the 33rd largest by enrollment of the 43 interventional ones that give a count, is one of 3 that started in 2006, is one of 24 with no phase, and was the 7th registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

6 of the 62 studies in Coronary Artery Disease with a site in India are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in India have not opened yet or have stopped. Only those recruiting at a site in India →

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 62 studies in Coronary Artery Disease with a site in India, or all of them as a file.
02

Study summary

OBJECTIVES:

The primary objective of this study is to assess the safety and efficacy of the Supralimus - Core™ Sirolimus Eluting Stent in de novo native vessel obstructive coronary artery disease.

STUDY DESIGN:

This is a single centre, prospective study. Approximately 105 patients were enrolled in the study. Patients were followed for twelve months post-procedure. All patients were to have a repeat angiography at 8 months.

STUDY POPULATION:

The study population consisted of approximately 105 patients with de novo native vessel obstructive coronary artery disease with no specific criteria. Patients from the daily practice were included. Patients had to meet all eligibility criteria for inclusion into the study.

ENDPOINTS:

The primary safety endpoint of the study is defined as Major Adverse Cardiac Events (MACE) at 30 days.

The primary efficacy endpoint is the in-stent binary restenosis rate at 8-month follow-up determined by off-line Quantitative Coronary Angiography.

The following secondary efficacy endpoints were assessed

  • Angiographic success
  • Procedure success
  • Quantitative Coronary Angiography derived vessel parameters in-stent and 5 mm proximal and 5 mm distal from the edge of the stent: acute gain, MLD, % DS, late loss, mean diameter. In-stent pre-, post and at 8-month follow-up.
  • Clinically justified Target Lesion Revascularization (TLR) at 12 months

The following secondary safety endpoints were assessed:

  • MACE until 12 months
  • Device related SAEs until 12 months
  • Angiographic stent thrombosis: Subacute (after procedure until 30 days) and Late (after 30 days until 12 months)
03

Conditions studied

  • Coronary Artery Disease

Keywords

  • Coronary artery disease
  • Supralimus-Core™
  • de novo native coronary artery lesion
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The patient must be >= 18 years of age;
  • Symptomatic ischemic heart disease (CCS class 1 -4 , Braunwald class IB, IC, IIB, IIC, IIIB,IIIC) and/or objective evidence of myocardial ischemia;
  • Vessel size of >= 2.5 and \<= 3.5mm.
  • Target lesions which can be covered by stent in a manner lesion stent ratio of at least 1.5.
  • Acceptable candidate for coronary artery bypass surgery (CABG);
  • Target lesion stenosis is >50% and \<100% (TIMI flow I) (visual estimate);
  • The patient has been informed of the nature of the study agrees to its provisions and has provided written , approved by the appropriate Medical Ethics Committee (MEC) or Institutional Review Board (IRB).

Exclusion criteria

Exclusion Criteria:

  • Women of ;
  • Impaired renal function (creatinine > 2.0 mg/dl or 177 µmol/l);
  • Any patient who has a count \< 100,000 cells/mm3 or > 700,000 cells/mm3, a WBC of \< 3,000 cells/mm3, or documented or suspected liver disease (including laboratory evidence of hepatitis);
  • Recipient of heart transplant;
  • Restenotic or lesion in graft.
  • Patient with a less than 12 months;
  • Known allergies to aspirin, clopidogrel bisulphate (Plavix), ticlopidine (Ticlid), heparin or stainless steel;
  • Any significant medical condition which in the investigator's opinion may interfere with the patient's optimal participation in the study;
  • Currently participating in an drug or another device study, or subject to inclusion in another investigational drug or another device study during follow-up.

Angiographic Exclusion criteria:

  • Unprotected left main coronary artery disease with >=50% stenosis;
  • Angiographic evidence of thrombus (thrombus larger than half the diameter of the vessel and/or requiring other interventions such as angiojet, exciser, thrombolysis, etc.);
  • \<= 30%;
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
105 participants (actual)

Study arms

  • Experimental
    Supralimus™ Core™ Sirolimus eluting stent

    Supralimus™ Core™ Sirolimus eluting stent manufactured by Sahajanand Medical Technologies Limited intended to treat coronary artery disease.

    Device: Supralimus-Core™ · Device: Supralimus™ Core™ Sirolimus eluting stent

Interventions

  • DeviceSupralimus-Core™

    Sirolimus Eluting Cobalt Chromium based coronary stent system

  • DeviceSupralimus™ Core™ Sirolimus eluting stent

    Supralimus™ Core™ Sirolimus eluting stent intended to treat coronary artery disease.

06

What researchers measure

Primary outcomes

  1. Primary safety endpoint: Major Adverse Cardiac Events (MACE)

    Time frame: 30 days

  2. Primary efficacy endpoint: In-stent binary restenosis rate determined by off-line Quantitative Coronary Angiography.

    Time frame: 8 Month

Secondary outcomes

  1. Secondary safety endpoints: - MACE until 12 months, Device related SAEs until 12 months, Angiographic stent thrombosis: Subacute (after procedure until 30 days) and Late (after 30 days until 12 months)

    Time frame: 12 months

  2. Secondary efficacy endpoints: Angiographic, Procedure success; acute gain, MLD, % DS, LL, mean diameter; In-stent pre-,post,8-month follow-up; Clinically justified TLR at 12 months

    Time frame: 12 months

07

Study locations

1 site
  • Max Heart and Vascular Institute
    New Delhi, 110017, India
08

References and documents

Publications

  • Seth A, Chandra P, Chouhan NS, Thakkar AS. A first-in-man study of sirolimus-eluting, biodegradable polymer coated cobalt chromium stent in real life patients. Indian Heart J. 2012 Nov-Dec;64(6):547-52. doi: 10.1016/j.ihj.2012.07.011. Epub 2012 Jul 27. PubMed 23253405 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2006, a primary completion of Jul 2007 and a completion of Mar 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 18, 2008
First posted
Dec 19, 2008
Start
Jul 2006
Primary completionActual
Jul 2007
CompletionActual
Mar 2008
Last update
May 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00811616
Lead sponsor
Sahajanand Medical Technologies Limited
Responsible party
Sponsor
First posted
Dec 19, 2008
Start date
Jul 2006
Primary completion
Jul 2007
Completion
Mar 2008
Last update
May 16, 2025

Study contacts

Dr. Ashok Seth
principal investigator · Escorts Heart Institute & Research Centre

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion